Lund, Sweden, 2015-11-16 18:00 CET (GLOBE NEWSWIRE) --
At the request of Progenics Pharmaceuticals, Inc (”Progenics”), the board of EXINI Diagnostics AB (publ) (”EXINI”) has today resolved to apply for voluntary removal of the shares from trading on First North.
Following completion of Progenics public offer to the shareholders of EXINI, Progenics controls over 90 per cent of the capital and the votes in EXINI. Progenics has also announced its intention to initiate a compulsory redemption of the remaining shares in EXINI that are not held by Progenics.
The company has requested that the last day of trading in the company’s shares on First North should be 30 November 2015, at the latest. The last day of trading on First North will be announced as soon as the company has received confirmation from First North.
Lund, November 16, 2015
EXINI Diagnostics AB (publ)
Board of Directors
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of medical images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as cancer, coronary heart disease, dementia and Parkinson's disease. EXINI is listed on the stock market NASDAQ OMX First North. Consensus acts as Certified Adviser.
________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 27, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
